Divis Laboratories Ltd | DIVI - Selling And Administration Expenses


Divis Laboratories Ltd reported INR3.4B in Selling and Administration Expenses for its fiscal quarter ending in June of 2025.





Selling And Administration Expenses Change Date
Alaunos Therapeutics USD 447K 138K Mar/2026
Aurobindo Pharma INR 12.77B 485.3M Sep/2025
Avita Medical AUD 19.03M 1.95M Dec/2025
Dianthus Therapeutics USD 12.47M 5.89M Mar/2026
Divis Laboratories Ltd INR 3.4B 10M Jun/2025
Ionis Pharmaceuticals USD 130.07M 20.92M Jun/2026
IQVIA Holdings USD 574M 72M Jun/2026
Lupin INR 11.06B 225.6M Sep/2025
Moderna USD 216M 43M Jun/2026
Organon & Co USD 434M 10M Jun/2026
Revvity USD 278.58M 24.69M Jun/2026
Tectonic Therapeutic USD 6.43M 2.99M Mar/2026
Tilray USD 24.85M 1.7M Sep/2025
Viatris USD 1.13B 205.7M Jun/2026
Xeris Pharmaceuticals USD 53.14M 10.51M Mar/2026